Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Chemomab Therapeutics Ltd.CMMB · Entity 7653 | Director | March 18, 2026 | March 31, 2026 |
| FILANA THERAPEUTICS, INC.SAVA · Entity 7294 | Director | May 23, 2025 | May 27, 2025 |
| Gain Therapeutics, Inc.GANX · Entity 6943 | Director | July 15, 2026 | July 17, 2026 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | June 04, 2026 | June 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Chemomab Therapeutics Ltd.
Report date March 18, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy American Depositary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $109.04 · Expires 2031-04-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report. |
| Stock option (right to buy American Depositary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $14.12 · Expires 2032-03-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report. |
| Stock option (right to buy American Depositary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2033-03-21 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report. |
| Stock option (right to buy American Depositary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2034-03-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report. |
| Stock option (right to buy American Depositary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $6.16 · Expires 2035-03-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F5: The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report. |
| Stock option (right to buy American Depositary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2036-03-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed |
Filing footnotes · ownership attribution and instrument terms
F1: The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.
F2: The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.
F3: The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.
F4: The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report.
F5: The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report.
FILANA THERAPEUTICS, INC.
Report date May 23, 2025 · Filed May 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.11 · Expires 2035-05-23 | Direct | 26,500 |
Reported balance
After 2025-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-23 · Grant · Acquired 26,500 · Balance 26,500 F1: Form 4 represents grant pursuant to the Amended Non-employee Director Compensation Program approved by stockholders on May 23, 2025. Stock options vest over a one (1) year period at a rate of 1/12 per month. |
Filing footnotes · ownership attribution and instrument terms
F1: Form 4 represents grant pursuant to the Amended Non-employee Director Compensation Program approved by stockholders on May 23, 2025. Stock options vest over a one (1) year period at a rate of 1/12 per month.
Gain Therapeutics, Inc.
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2036-07-15 | Direct | 25,000 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.
Sarepta Therapeutics, Inc.
Report date June 04, 2026 · Filed June 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,407 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 16,875 · Balance 48,407 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 12:32 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001104659-26-084438 · tm2620629-5_4seq1.xml · derivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-07-15 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| June 04, 2026 Filed Jun 6, 2026 00:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 16,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-260250 · ownership.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,407 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting. Read SEC document |
| January 29, 2026 Filed Jan 30, 2026 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001193125-26-029895 · ownership.xml · derivative · entry 3 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2026 Filed Jan 30, 2026 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 6,780 | $21.23 | $143,939.40 |
DisclosureSEC source: 0001193125-26-029895 · ownership.xml · nonDerivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,532 F1 · kind: Represents shares withheld by the Issuer to satisfy payment by the Reporting Person of the option exercise price. The Reporting Person holds the exercised shares not wittheld by the Issuer. Read SEC document |
| January 29, 2026 Filed Jan 30, 2026 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 10,500 | $13.71 | $143,955.00 |
DisclosureSEC source: 0001193125-26-029895 · ownership.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2025 Filed Jun 25, 2025 21:30 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001641172-25-016535 · ownership.xml · derivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2025, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| May 23, 2025 Filed May 27, 2025 20:19 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 26,500 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001437749-25-018497 · rdgdoc.xml · derivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,500 Underlying: Common Stock · 26,500 shares Expires 2035-05-23 F1 · derivative.exercise_date: Form 4 represents grant pursuant to the Amended Non-employee Director Compensation Program approved by stockholders on May 23, 2025. Stock options vest over a one (1) year period at a rate of 1/12 per month. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Options (right to buy) · Derivative | 9,746 | $0.00 Strike: $25.18 | $0.00 |
DisclosureSEC source: 0000950170-25-039037 · ownership.xml · derivative · entry 3 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,746 shares Expires 2025-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 2,491 | $99.64 | $248,203.24 |
DisclosureSEC source: 0000950170-25-039037 · ownership.xml · nonDerivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,812 F1 · shares: The shares were sold to cover the exercise price relating to the exercise of stock options to purchase shares, which are scheduled to expire in 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.64 and $99.87, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 9,746 | $25.18 | $245,404.28 |
DisclosureSEC source: 0000950170-25-039037 · ownership.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Options (right to buy) · Derivative | 4,792 | $0.00 Strike: $99.69 | $0.00 |
DisclosureSEC source: 0000950170-25-037522 · ownership.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,557 Underlying: Common Stock · 4,792 shares Expires 2035-03-10 Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,383 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-037522 · ownership.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,557 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 10, 2026. Read SEC document |
| June 24, 2024 Filed Jun 27, 2024 01:30 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001493152-24-025336 · ownership.xml · derivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2024, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:05 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $21.11 | $0.00 |
DisclosureSEC source: 0001437749-24-016227 · rdgdoc.xml · derivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-05-09 F1 · derivative.exercise_date: Form 4 represents grant pursuant to the Non-employee Director Compensation Program approved by stockholders on May 4, 2023. Stock options vest over a one (1) year period at a rate of 1/12 per month. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 3,679 | $0.00 Strike: $128.67 | $0.00 |
DisclosureSEC source: 0000950170-24-026617 · ownership.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,679 Underlying: Common Stock · 3,679 shares Expires 2034-03-01 Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026617 · ownership.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,174 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 1, 2025. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 22:06 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $21.71 | $0.00 |
DisclosureSEC source: 0001437749-23-034025 · rdgdoc.xml · derivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: The stock option vests over three (3) years at a rate of 1/36th each month. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:37 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001209191-23-039720 · doc4.xml · derivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2033-06-23 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 23, 2023, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| March 16, 2023 Filed Mar 23, 2023 11:36 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 11,884 | $0.00 Strike: $27.26 | $0.00 |
DisclosureSEC source: 0001178913-23-001113 · zk2329429.xml · derivative · entry 3 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,884 Underlying: American Depositary Shares · 11,884 shares Expires 2031-04-19 F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F5 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 16, 2023 Filed Mar 23, 2023 11:36 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 6,820 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001178913-23-001113 · zk2329429.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,820 Underlying: American Depositary Shares · 6,820 shares Expires 2032-03-07 F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F4 · derivative.exercise_date: These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors. F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 16, 2023 Filed Mar 23, 2023 11:36 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 6,857 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001178913-23-001113 · zk2329429.xml · derivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,857 Underlying: American Depositary Shares · 6,857 shares Expires 2033-03-21 F1 · derivative.exercise_date: These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 3,257 | $0.00 Strike: $155.99 | $0.00 |
DisclosureSEC source: 0001209191-23-017405 · doc4.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,257 Underlying: Common Stock · 3,257 shares Expires 2033-03-06 Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017405 · doc4.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,328 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 6, 2024. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:08 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-22-051007 · doc4.xml · derivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2032-09-20 F1 · derivative.exercise_date: The option vests fully on the day before the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:07 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 5,077 | $0.00 Strike: $80.42 | $0.00 |
DisclosureSEC source: 0001209191-22-017353 · doc4.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,077 Underlying: Common Stock · 5,077 shares Expires 2032-03-07 Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:07 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017353 · doc4.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,805 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 7, 2023. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 21:07 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 6,820 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001178913-22-001024 · zk2227456.xml · derivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,820 Underlying: American Depositary Shares · 6,820 shares Expires 2032-03-07 F1 · derivative.exercise_date: These options vest and become exercisable in their entirety on March 16, 2023. F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 21:16 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 11,884 | $0.00 Strike: $27.26 | $0.00 |
DisclosureSEC source: 0001104659-21-053235 · tm2113689-5_4.xml · derivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,884 Underlying: American Depositary Shares · 11,884 shares Expires 2031-04-19 F1 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| April 19, 2021 Filed Mar 9, 2022 21:07 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 11,884 | $0.00 Strike: $27.26 | $0.00 |
DisclosureSEC source: 0001178913-22-001024 · zk2227456.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,884 Underlying: American Depositary Shares · 11,884 shares Expires 2031-04-19 F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F4 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 5,518 | $0.00 Strike: $87.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018419 · doc4.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,518 Underlying: Common Stock · 5,518 shares Expires 2031-03-03 Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018419 · doc4.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,852 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 3,685 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014235 · doc4.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 Underlying: Common Stock · 3,685 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014235 · doc4.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,126 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 3,213 | $0.00 Strike: $145.48 | $0.00 |
DisclosureSEC source: 0001209191-19-016034 · doc4.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213 Underlying: Common Stock · 3,213 shares Expires 2029-03-04 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016034 · doc4.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,051 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 4,820 | $0.00 Strike: $71.45 | $0.00 |
DisclosureSEC source: 0001209191-18-017793 · doc4.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,820 Underlying: Common Stock · 4,820 shares Expires 2028-03-05 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of the Issuer's 2018 Annual Meeting of Stockholders. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 3,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017793 · doc4.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,418 F1 · shares: Each restricted stock award represents the right to receive one share of common stock and will vest in full on the first year anniversary of the Issuer's 2018 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:46 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020686 · doc4.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2027-03-10 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:46 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020686 · doc4.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.